STAT

APRIL 25, 2024

Andrew Bowman, a veterinary epidemiologist at Ohio State University, had a hunch. He had been struck by the huge amounts of H5N1 virus he’d seen in milk from cows infected with the bird flu and thought that at least some virus was getting off of farms and going downstream — onto store shelves. He knew the Food and Drug Administration was working on its own national survey of the milk supply.

364

364

PharmaVoice

APRIL 25, 2024

From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.

130

130

STAT

APRIL 25, 2024

University of Washington professor David Baker has made a name for himself by borrowing computer science concepts like machine learning and artificial intelligence to solve problems in biology. A few years ago, his lab surprised scientists by constructing an AI-powered protein-folding prediction system rivaling Google’s DeepMind AlphaFold. Now Baker is pushing forward in a different area of drug discovery research.

Compounding 339

Compounding Drug Development 339

The Guardian - Pharmaceutical Industry

APRIL 25, 2024

Exclusive: MSF calls for transparency after its bill for a trial of TB treatment came to a fraction of the billions claimed by pharmaceutical companies Doctors have for the first time released details of their spending on a major clinical trial, demonstrating that the true cost of developing a medicine may be far less than the billions of dollars claimed by the pharmaceutical industry.

Pharmaceutical Companies 125

Pharmaceutical Companies Pharmaceutical Companies 125

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

APRIL 25, 2024

After stratospheric levels of hype, early evidence may be bringing generative artificial intelligence down to Earth. A series of recent research papers by academic hospitals has revealed significant limitations of large language models (LLMs) in medical settings, undercutting common industry talking points that they will save time and money, and soon liberate clinicians from the drudgery of documentation.

Documentation 323

Documentation Hospitals 323

Express Pharma

APRIL 25, 2024

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy. Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales of $4 billion by 2027, according to an analyst consensus forecast by GlobalData.

Chemotherapy 116

Chemotherapy 116

BioPharma Dive

APRIL 25, 2024

The layoffs will impact some 2,200 employees, the company said, as it repositions its business ahead of looming patent expirations for top-selling products.

118

118

STAT

APRIL 25, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Why did the dairy cow cross state lines? After weeks of concern that the U.S. Department of Agriculture wasn’t doing enough to quell the spread of H5N1 bird flu, the agency announced Wednesday that it’s going to require testing for dairy cattle crossing sta

322

322

BioPharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

119

119

STAT

APRIL 25, 2024

In my work as a pediatric psychologist, I’ve been seeing a surge in the number of families with transgender or nonbinary children who are moving to Connecticut, where I live and work. In the past month, a real estate agent colleague has worked with 30 families with transgender children who were trying to find homes in central Connecticut, where they could get access to gender-affirming care.

317

317

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

The Pharmacist

APRIL 25, 2024

Five projects that use drones to deliver medicines and medical supplies have been given £500,000 between them as part of a development programme co-funded by the government. The programme, called the UKRI Future Flight Challenge, is a £300m project to support the creation of an ‘aviation ecosystem’ to help accelerate the introduction of drones and […] The post Projects using drones to deliver medicines receive investment appeared first on The Pharmacist.

105

105

STAT

APRIL 25, 2024

After months of sustained criticism, Vertex Pharmaceuticals reached an agreement to provide a pricey cystic fibrosis treatment in South Africa, but the move prompted a mixed reaction from consumer groups, some of which complained the deal is geared toward people with expensive health coverage. Under the arrangement, the company is making its Trikafta medication available through a government mechanism that allows a medicine that is not registered for sale in the country to be made available to i

Drug Pricing 304

Drug Pricing 304

Outsourcing Pharma

APRIL 25, 2024

Wuxi AppTec says recent allegations made by the US government that it has shared clients' data with Beijing without consent are âmisleadingâ and âinaccurateâ.

111

111

STAT

APRIL 25, 2024

Christopher Boerner, 53, took over as the chief executive officer of Bristol Myers Squibb last November, and immediately made a big move: a series of three acquisitions totaling $24 billion that would give BMS a new schizophrenia drug, a targeted cancer medicine, and radiopharmaceuticals used to treat cancer. On Thursday, Bristol released first quarter earnings and showed the price for those acquisitions.

294

294

Pharma Times

APRIL 25, 2024

The tool will help people find out about clinical trials for myeloma, MGUS, SMM and AL amyloidosis

130

130

STAT

APRIL 25, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning. Here in Chicago, residents are reeling over the  removal of the famed rat hole,  a rat-shaped indentation on a piece of sidewalk that drew crowds, fans, and even a proposal and a marriage. The need-to-know this morning AstraZeneca reported first-quarter  sales and profits  that topped analyst estimates, buoyed by its blockb

Hospitals 273

Hospitals Drug Pricing 273

The Pharmacist

APRIL 25, 2024

Community Pharmacy England (CPE) has suggested that the ‘extended period of time’ taken to determine this month’s concessionary prices was ‘likely’ due to an imposed change designed to manage margins. In a newsletter sent last night, the negotiator said it was still waiting for the Department of Health and Social Care (DHSC) to determine price […] The post Price concession changes 'likely' behind April wait, suggests CPE appeared first on The Pharmacist.

Community Pharmacies 100

Community Pharmacies 100

STAT

APRIL 25, 2024

Dear Readers, Please bear with me as I brag about two of STAT’s most accomplished (and humble) reporters: Casey Ross and Bob Herman.

300

300

BioPharma Dive

APRIL 25, 2024

The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.

115

115

STAT

APRIL 25, 2024

Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of motor vehicles passing by is picking up, and the official mascots are busy foraging for snacks on the official grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is orange cream.

Packaging 225

Packaging Diabetes 225

Outsourcing Pharma

APRIL 25, 2024

Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.

98

98

STAT

APRIL 25, 2024

Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. Each year, STAT chooses a new class of Wunderkinds, showcasing stars of science and medicine who are in the midst of launching their careers. Join for a conversation with past all-star Wunderkinds to see where they are now, how their journeys have unfolded, and hear their most inspiring and innovative ideas.

222

222

Pharma Times

APRIL 25, 2024

X-linked Charcot-Marie-Tooth is the second most common form of the rare peripheral neuropathy disease

115

115

STAT

APRIL 25, 2024

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Last night, we held our 2024 STATUS List dinner, honoring  50 influential people shaping the future of health, medicine and life sciences. It was an amazing evening, and a chance to eat and chat with some brilliant and engaging honorees.

213

213

Pharmaceutical Commerce

APRIL 25, 2024

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

105

105

STAT

APRIL 25, 2024

The Hatch-Waxman Act of 1984, which gave rise to the modern generic drug market, was one of the most significant cost-reducing policy innovations of the last 40 years. In 2021 alone, the use of generic and biosimilar drugs saved $373 billion in health expenditures. More than 90% of prescriptions filled that year were for generics or biosimilars, up from just over 18% the year that Hatch-Waxman was passed.

Prescription Filling 217

Prescription Filling Biosimilars Chemotherapy 217

The Script

APRIL 25, 2024

We've all seen the rates of burnout rise over the last decade. Our team at Rx relief explains how management can support.

Pharmacy Management 105

Pharmacy Management 105

Express Pharma

APRIL 25, 2024

Lupin Digital Health’s Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organisation (CDSCO). A press statement informed that Lyfe is now India’s first clinically proven remote cardiac rehabilitation program, designed to enhance heart health and quality of life. By providing tailored, accessible solutions in the comfort of patients’ homes, Lyfe empowers individuals to confidently manage their heart health.

104

104

Pharmaceutical Technology

APRIL 25, 2024

Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.

98

98

European Pharmaceutical Review

APRIL 25, 2024

Research on the global pharmaceutical parenteral packaging market by InsightAce Analytic Pvt. Ltd. has predicted that the sector will value $18.85 billion by 2031. This is aligned with a CAGR of 4.47 percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally.

Packaging 84

Packaging Generic Medicine Diabetes Vaccines 84

World Pharma News

APRIL 25, 2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the AB-1002 program. AB-1002 is an investigational one-time gene therapy that is administered to the heart with the intention of helping to promote the production of a constitutively active form of protein inhibitor 1 (I-1c) designed to block the action

82

82

Express Pharma

APRIL 25, 2024

Strategic collaboration to leverage BigHat’s AI/ML (Artificial Intelligence / Machine Learning) guided Milliner platform to design high-quality next-generation protein therapeutics BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company.

105

105

pharmaphorum

APRIL 25, 2024

On today’s podcast, host Jonah Comstock is joined by Dr Amit Etkin, founder and CEO of Alto Neuroscience, a recently IPO'd biotech that wants to bring precision medicine to psychiatry. But what do we mean when we talk about precision, especially in a discipline like mental health that has historically involved a lot of objectivity?

80

80

European Pharmaceutical Review

APRIL 25, 2024

A study has determined that for biologics subject to multiple stresses during bioprocessing and manufacturing , “exposure to air-liquid interfacial dilatational stress is the predominant mechanism impacting protein particle formation, [both] at the interface and in the bulk solution” Researchers established a “unique” set-up using a peristaltic pump and a Langmuir-Pockels trough to study the impact of hydrodynamic shear stress due to pumping and interfacial dilatational stress, on the form

70

70

Pharmafile

APRIL 25, 2024

Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement with Ono Pharmaceutical. Under the terms of this agreement, the two companies will collaboratively develop a candidate for Ono’s oncology target using Prism’s PepMetrics technology. Once a candidate is identified, Prism is expected to license its right to Ono for […] The post Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement appeared first on Pharmafile.

63

63